Truist initiated coverage of Tandem Diabetes (TNDM) with a Hold rating and $24 price target New launches should improve Tandem’s position in underpenetrated/growth Type 1 and Type 2 diabetes markets and the company can enhance its competitive positioning as Mobi and future designs eventually come to market, but the company still remains over indexed to a slower growth segment that is margin disadvantaged vs. patch, the analyst tells investors in a research note. Truist expects Tandem to grow revenues at 11% for 2024-2028, even as it loses share within growing markets.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes announces agreement with Abbott to develop diabetes solutions
- Tandem Diabetes Care: Strategic Initiatives and Product Launches Drive Long-Term Growth Potential
- Balanced Outlook on Tandem Diabetes Care: Growth Opportunities Amid Strategic Challenges
- Tandem Diabetes Care Settles Patent Disputes with Roche
- Tandem Diabetes, Roche enter patent settlement agreement